Cargando…

Exogenous Insulin Antibody Syndrome in Patients with Type 2 Diabetes

BACKGROUND: Exogenous insulin antibody syndrome (EIAS) is an immunological disorder caused by circulating insulin antibodies (IAs), featuring hypersensitivity to exogenous insulin and insulin resistance. With the wide use of recombinant human insulin and insulin analogs, there has been a significant...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Chen-Yu, Ye, Xiao-Mei, Lu, Jia-Ping, Jin, Hai-Ying, Xu, Wei-Wei, Wang, Ping, Zhang, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312206/
https://www.ncbi.nlm.nih.gov/pubmed/37398942
http://dx.doi.org/10.2147/DMSO.S410349
_version_ 1785066895476523008
author Han, Chen-Yu
Ye, Xiao-Mei
Lu, Jia-Ping
Jin, Hai-Ying
Xu, Wei-Wei
Wang, Ping
Zhang, Min
author_facet Han, Chen-Yu
Ye, Xiao-Mei
Lu, Jia-Ping
Jin, Hai-Ying
Xu, Wei-Wei
Wang, Ping
Zhang, Min
author_sort Han, Chen-Yu
collection PubMed
description BACKGROUND: Exogenous insulin antibody syndrome (EIAS) is an immunological disorder caused by circulating insulin antibodies (IAs), featuring hypersensitivity to exogenous insulin and insulin resistance. With the wide use of recombinant human insulin and insulin analogs, there has been a significant proliferation of EIAS. CASE REPORT: We describe two cases of diabetes mellitus (DM) with hyperinsulinemia and high serum levels of IAs. They had never been exposed to methimazole, glutathione, lipoic acid, and other sulfhydryl drugs, but they all received insulin treatment. The patient in case 1 had recurrent hypoglycemia before hospitalization. A prolonged oral glucose tolerance test (OGTT) showed hypoglycemia with inappropriately high insulin levels. The patient in case 2 was hospitalized for diabetic ketosis. An OGTT indicated hyperglycemia with hyperinsulinemia and low levels of C-peptide. IAs induced by exogenous insulin in the two patients with DM were positive at high titers, prompting a diagnosis of another condition—EIAS. CONCLUSION: We discussed the differences between these two cases of EIAS in clinical manifestations and treatment and summarized all patients of EIAS treated in our department to date.
format Online
Article
Text
id pubmed-10312206
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-103122062023-07-01 Exogenous Insulin Antibody Syndrome in Patients with Type 2 Diabetes Han, Chen-Yu Ye, Xiao-Mei Lu, Jia-Ping Jin, Hai-Ying Xu, Wei-Wei Wang, Ping Zhang, Min Diabetes Metab Syndr Obes Case Series BACKGROUND: Exogenous insulin antibody syndrome (EIAS) is an immunological disorder caused by circulating insulin antibodies (IAs), featuring hypersensitivity to exogenous insulin and insulin resistance. With the wide use of recombinant human insulin and insulin analogs, there has been a significant proliferation of EIAS. CASE REPORT: We describe two cases of diabetes mellitus (DM) with hyperinsulinemia and high serum levels of IAs. They had never been exposed to methimazole, glutathione, lipoic acid, and other sulfhydryl drugs, but they all received insulin treatment. The patient in case 1 had recurrent hypoglycemia before hospitalization. A prolonged oral glucose tolerance test (OGTT) showed hypoglycemia with inappropriately high insulin levels. The patient in case 2 was hospitalized for diabetic ketosis. An OGTT indicated hyperglycemia with hyperinsulinemia and low levels of C-peptide. IAs induced by exogenous insulin in the two patients with DM were positive at high titers, prompting a diagnosis of another condition—EIAS. CONCLUSION: We discussed the differences between these two cases of EIAS in clinical manifestations and treatment and summarized all patients of EIAS treated in our department to date. Dove 2023-06-26 /pmc/articles/PMC10312206/ /pubmed/37398942 http://dx.doi.org/10.2147/DMSO.S410349 Text en © 2023 Han et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Case Series
Han, Chen-Yu
Ye, Xiao-Mei
Lu, Jia-Ping
Jin, Hai-Ying
Xu, Wei-Wei
Wang, Ping
Zhang, Min
Exogenous Insulin Antibody Syndrome in Patients with Type 2 Diabetes
title Exogenous Insulin Antibody Syndrome in Patients with Type 2 Diabetes
title_full Exogenous Insulin Antibody Syndrome in Patients with Type 2 Diabetes
title_fullStr Exogenous Insulin Antibody Syndrome in Patients with Type 2 Diabetes
title_full_unstemmed Exogenous Insulin Antibody Syndrome in Patients with Type 2 Diabetes
title_short Exogenous Insulin Antibody Syndrome in Patients with Type 2 Diabetes
title_sort exogenous insulin antibody syndrome in patients with type 2 diabetes
topic Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10312206/
https://www.ncbi.nlm.nih.gov/pubmed/37398942
http://dx.doi.org/10.2147/DMSO.S410349
work_keys_str_mv AT hanchenyu exogenousinsulinantibodysyndromeinpatientswithtype2diabetes
AT yexiaomei exogenousinsulinantibodysyndromeinpatientswithtype2diabetes
AT lujiaping exogenousinsulinantibodysyndromeinpatientswithtype2diabetes
AT jinhaiying exogenousinsulinantibodysyndromeinpatientswithtype2diabetes
AT xuweiwei exogenousinsulinantibodysyndromeinpatientswithtype2diabetes
AT wangping exogenousinsulinantibodysyndromeinpatientswithtype2diabetes
AT zhangmin exogenousinsulinantibodysyndromeinpatientswithtype2diabetes